A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON^® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany

ralesci Congresses with "Zero Impact®" on the environmentive drug for chronic hyperuricaemia in gout.D VitaPCR^® POC instrument.

On August 20th the German Minister of Health, Jens Spahn visited the Red Cross Hospital of Mölln-Ratzeburg.

A.Menarini Diagnostics Announces Agreement with Skyla Corporation in the area of Point of Care Testing

Hsinchu, Taiwan and Florence, Italy, July 24th, 2020

Menarini Diagnostics announces Technology Transfer Agreement to develop its own COVID 19 RT PCR assay

Florence and Trieste, Italy, July 16th, 2020

First Previous 6 7 8 9 10 11 12 13 14 15 Next

Archivio News

i nostri valori

4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.

A. Menarini Diagnostics s.r.l - Società con socio unico - Sede della società: Via Sette Santi 3 - 50131 Firenze - Numero di iscrizione registro imprese: 05688870483 - Ufficio del registro delle imprese: Firenze
Capitale: € 30.000.000 I.V. - Capitale risultante dall’ultimo bilancio: € 30.000.000 - Società soggetta all’attività di direzione e coordinamento di A. Menarini Industrie Farmaceutiche Riunite Srl

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

September 3rd, 2020 – Firenze, Italy and Bad Homburg, Germany

ralesci Congresses with "Zero Impact®" on the environmentive drug for chronic hyperuricaemia in gout.D VitaPCR® POC instrument.

A.Menarini Diagnostics Announces Agreement with Skyla Corporation in the area of Point of Care Testing

Hsinchu, Taiwan and Florence, Italy, July 24th, 2020

Menarini Diagnostics announces Technology Transfer Agreement to develop its own COVID 19 RT PCR assay

i nostri valori

A.MENARINI DIAGNOSTICS and BIOACTIVA DIAGNOSTICA GMBH SIGN AN EXCLUSIVE AGREEMENT FOR LIOFERON^® TB/LTBI, A TEST TO DIAGNOSE LATENT TUBERCULOSIS INFECTION.

ralesci Congresses with "Zero Impact®" on the environmentive drug for chronic hyperuricaemia in gout.D VitaPCR^® POC instrument.